• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Forma Therapeutics Holdings Inc. (Amendment)

    2/14/22 3:13:03 PM ET
    $FMTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $FMTX alert in real time by email
    SC 13G/A 1 schedule13g.htm
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     

     
    SCHEDULE 13G
     
     
     
    Under the Securities Exchange Act of 1934
     
     
     
    (Amendment No. 2)*
     

     
    Forma Therapeutics Holdings, Inc.
     
     
    (Name of Issuer)
     

     
    Common Stock
     
     
    (Title of Class of Securities)
     

     
    34633R104
     
     
    (CUSIP Number)
     

     
    December 31, 2021
     
     
    (Date of Event which Requires Filing of this Statement)
     


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    [ ]            Rule 13d-1(b)
    [x]            Rule 13d-1(c)
    [ ]            Rule 13d-1(d)
    ___________________________________
    *  The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


    1
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)
    Cormorant Global Healthcare Master Fund, LP
    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a)            [ ]
     
    (b)            [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    Cayman Islands

    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5  Sole Voting Power
     
    0 shares
    6  Shared Voting Power
     
    3,171,644 shares
     
    Refer to Item 4 below.
    7  Sole Dispositive Power
     
    0 shares
    8  Shared Dispositive Power
     
    3,171,644 shares
    Refer to Item 4 below.

    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    3,171,644 shares
    Refer to Item 4 below.
     
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
        [ ] N/A
     
    11
    Percent of Class Represented by Amount in Row (9)*
     
    6.69%
    Refer to Item 4 below.
     
    12
    Type of Reporting Person (See Instructions)
    PN (Partnership)
     


    1
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)
     
    Cormorant Global Healthcare GP, LLC
     
    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a)            [ ]
     
    (b)            [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    Delaware

    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5  Sole Voting Power
     
    0 shares
    6  Shared Voting Power
     
    3,171,644 shares
     
    Refer to Item 4 below.
    7  Sole Dispositive Power
     
    0 shares
    8  Shared Dispositive Power
     
    3,171,644 shares
    Refer to Item 4 below.

    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    3,171,644 shares
    Refer to Item 4 below.
     
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
        [ ] N/A
     
    11
    Percent of Class Represented by Amount in Row (9)*
     
    6.69%
    Refer to Item 4 below.
     
    12
    Type of Reporting Person (See Instructions)
     
    OO (Limited Liability Company)
     


    1
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)
    Cormorant Private Healthcare Fund II, LP
    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a)            [ ]
     
    (b)            [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    Delaware

    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5  Sole Voting Power
     
    0 shares
    6  Shared Voting Power
     
    1,468,354 shares
     
    Refer to Item 4 below.
    7  Sole Dispositive Power
     
    0 shares
    8  Shared Dispositive Power
     
    1,468,354 shares
    Refer to Item 4 below.

    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    1,468,354 shares
    Refer to Item 4 below.
     
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
        [ ] N/A
     
    11
    Percent of Class Represented by Amount in Row (9)*
     
    3.10%
    Refer to Item 4 below.
     
    12
    Type of Reporting Person (See Instructions)
    PN (Partnership)
     


    1
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)
     
    Cormorant Private Healthcare GP II, LLC
     
    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a)            [ ]
     
    (b)            [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    Delaware

    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5  Sole Voting Power
     
    0 shares
    6  Shared Voting Power
     
    1,468,354 shares
     
    Refer to Item 4 below.
    7  Sole Dispositive Power
     
    0 shares
    8  Shared Dispositive Power
     
    1,468,354 shares
    Refer to Item 4 below.

    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    1,468,354 shares
    Refer to Item 4 below.
     
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
        [ ] N/A
     
    11
    Percent of Class Represented by Amount in Row (9)*
     
    3.10%
    Refer to Item 4 below.
     
    12
    Type of Reporting Person (See Instructions)
     
    OO (Limited Liability Company)
     


    1
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)
     
    Cormorant Asset Management, LP
     
    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a)            [ ]
     
    (b)            [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    Delaware

    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5  Sole Voting Power
     
    0 shares
    6  Shared Voting Power
     
    4,639,998 shares
    Refer to Item 4 below.
    7  Sole Dispositive Power
     
    0 shares
    8  Shared Dispositive Power
     
    4,639,998 shares
    Refer to Item 4 below.

    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    4,639,998 shares
    Refer to Item 4 below.
     
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
        [ ] N/A
     
    11
    Percent of Class Represented by Amount in Row (9)*
     
    9.79%
    Refer to Item 4 below.
     
    12
    Type of Reporting Person (See Instructions)
     
    PN (Partnership)
     


    1
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)
     
    Bihua Chen
     
    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a)            [ ]
     
    (b)            [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    United States

    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5  Sole Voting Power
     
    0 shares
    6  Shared Voting Power
     
    4,639,998 shares
    Refer to Item 4 below.
    7  Sole Dispositive Power
     
    0 shares
    8  Shared Dispositive Power
     
    4,639,998 shares
    Refer to Item 4 below.

    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    4,639,998 shares
    Refer to Item 4 below.
     
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
        [ ] N/A
     
    11
    Percent of Class Represented by Amount in Row (9)*
     
    9.79%
    Refer to Item 4 below.
     
    12
    Type of Reporting Person (See Instructions)
     
    IN (Individual)
     

    Item 1.
    (a)
    Name of Issuer
     
    Forma Therapeutics Holdings, Inc.
     
    (b)
    Address of Issuer’s Principal Executive Offices
     
     
    300 North Beacon Street, Suite 501, Watertown, MA 02472

    Item 2.
    (a)
    Name of Person Filing
     
    Cormorant Global Healthcare Master Fund, LP
    Cormorant Global Healthcare GP, LLC
    Cormorant Private Healthcare Fund II, LP
    Cormorant Private Healthcare GP II, LLC
    Cormorant Asset Management, LP
    Bihua Chen
     
    (b)
    Address of Principal Business Office or, if none, Residence
     
    200 Clarendon Street, 52nd Floor
    Boston, MA 02116
     
    (c)
    Citizenship
     
     
    Cormorant Global Healthcare Master Fund, LP - Cayman Islands
    Cormorant Global Healthcare GP, LLC - Delaware
    Cormorant Private Healthcare Fund II, LP - Delaware
    Cormorant Private Healthcare GP II, LLC - Delaware
    Cormorant Asset Management, LP - Delaware
    Bihua Chen - United States
     
    (d)
    Title of Class of Securities
     
    Common Stock
     
    (e)
    CUSIP Number
     
    34633R104


    Item 3.
    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)



    [ ]



    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
    (b)
    [ ]
    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c)
    [ ]
    Insurance Company as defined in Section 3(a)(19) of the Act
    (d)
    [ ]
    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
    (e)
    [ ]
    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
    (f)
    [ ]
    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
    (g)
    [ ]
    A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)
    [ ]
    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)
    [ ]
    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)
    [ ]
    A non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J);
    (k)
    [ ]
    Group, in accordance with §240.13d-1(b)(1)(ii)(K).

    Item 4.
    Ownership***
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
    (a)
    Amount Beneficially Owned***
     
     
    Cormorant Global Healthcare Master Fund, LP – 3,171,644 shares
    Cormorant Global Healthcare GP, LLC – 3,171,644 shares
    Cormorant Private Healthcare Fund II, LP – 1,468,354 shares
    Cormorant Private Healthcare GP II, LLC – 1,468,354 shares
    Cormorant Asset Management, LP – 4,639,998 shares
    Bihua Chen – 4,639,998 shares
    (b)
    Percent of Class
     
     
    Cormorant Global Healthcare Master Fund, LP – 6.69%
    Cormorant Global Healthcare GP, LLC – 6.69%
    Cormorant Private Healthcare Fund II, LP – 3.10%
    Cormorant Private Healthcare GP II, LLC – 3.10%
    Cormorant Asset Management, LP – 9.79%
    Bihua Chen – 9.79%

    (c)
    Number of shares as to which such person has:
     
     
    (i)
    sole power to vote or to direct the vote
       

    Cormorant Global Healthcare Master Fund, LP - 0 shares
    Cormorant Global Healthcare GP, LLC - 0 shares
    Cormorant Private Healthcare Fund II, LP – 0 shares
    Cormorant Private Healthcare GP II, LLC – 0 shares
    Cormorant Asset Management, LP - 0 shares
    Bihua Chen - 0 shares
     
     
    (ii)
    shared power to vote or to direct the vote
       
     
    Cormorant Global Healthcare Master Fund, LP – 3,171,644 shares
    Cormorant Global Healthcare GP, LLC – 3,171,644 shares
    Cormorant Private Healthcare Fund II, LP – 1,468,354 shares
    Cormorant Private Healthcare GP II, LLC – 1,468,354 shares
    Cormorant Asset Management, LP – 4,639,998 shares
    Bihua Chen – 4,639,998 shares
     
    (iii)
    sole power to dispose or to direct the disposition of
       

    Cormorant Global Healthcare Master Fund, LP - 0 shares
    Cormorant Global Healthcare GP, LLC - 0 shares
    Cormorant Private Healthcare Fund II, LP – 0 shares
    Cormorant Private Healthcare GP II, LLC – 0 shares
    Cormorant Asset Management, LP - 0 shares
    Bihua Chen - 0 shares
     
     
    (iv)
    shared power to dispose or to direct the disposition of
       
     
    Cormorant Global Healthcare Master Fund, LP – 3,171,644 shares
    Cormorant Global Healthcare GP, LLC – 3,171,644 shares
    Cormorant Private Healthcare Fund II, LP – 1,468,354 shares
    Cormorant Private Healthcare GP II, LLC – 1,468,354 shares
    Cormorant Asset Management, LP – 4,639,998 shares
    Bihua Chen – 4,639,998 shares

    *** Shares reported herein for Cormorant Asset Management, LP represent shares which are beneficially by Cormorant Global Healthcare Master Fund, LP (the “Master Fund”) and Cormorant Private Healthcare Fund II, LP (“Fund II”), as reported herein).  Cormorant Global Healthcare GP, LLC, and Cormorant Private Healthcare GP II, LLC serve as the general partners of the Master Fund and Fund II, respectively. Cormorant Asset Management, LP serves as the investment manager to the Master Fund and Fund II.  Bihua Chen serves as the managing member of Cormorant Global Healthcare GP, LLC, Cormorant Private Healthcare GP II, LLC and the general partner of Cormorant Asset Management, LP.  Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or his pecuniary interest therein.
    The percentages reported herein with respect to the Reporting Persons’ holdings are calculated based upon a statement in the Issuer’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2021, as filed with the Securities and Exchange Commission on November 12, 2021, that there were 47,404,601 shares of Common Stock outstanding as of November 9, 2021.

    Item 5.
    Ownership of Five Percent or Less of a Class
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [  ].
    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person
    Not applicable.
    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company
    Not applicable.
    Item 8.
    Identification and Classification of Members of the Group
    Not applicable.
    Item 9.
    Notice of Dissolution of Group
    Not applicable.
    Item 10.
    Certification
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    Exhibits     Exhibit


    99.1                  Joint Filing Agreement by and among the Reporting Persons, incorporated by reference to Exhibit 99.1 to Schedule 13G filed by the Reporting Persons with the Securities and Exchange Commission on July 6, 2020.

    SIGNATURE
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this Statement is true, complete and correct.
    February 14, 2022


    CORMORANT GLOBAL HEALTHCARE MASTER FUND, LP
    By: Cormorant Global Healthcare GP, LLC
    its General Partner

    By: /s/ Bihua Chen
    Bihua Chen, Managing Member

    CORMORANT GLOBAL HEALTHCARE GP, LLC

    By: /s/ Bihua Chen
    Bihua Chen, Managing Member

    CORMORANT PRIVATE HEALTHCARE FUND II, LP
    By: Cormorant Global Healthcare GP II, LLC
    its General Partner

    By: /s/ Bihua Chen
    Bihua Chen, Managing Member

    CORMORANT PRIVATE HEALTHCARE GP II, LLC

    By: /s/ Bihua Chen
    Bihua Chen, Managing Member

    CORMORANT ASSET MANAGEMENT, LP
    By: Cormorant Asset Management GP, LLC
    its General Partner

    By: /s/ Bihua Chen
    Bihua Chen, Managing Member

    /s/ Bihua Chen
    Bihua Chen
    Get the next $FMTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $FMTX

    DatePrice TargetRatingAnalyst
    6/13/2022$46.00 → $21.00Overweight
    Cantor Fitzgerald
    11/12/2021$54.00 → $40.00Outperform
    SVB Leerink
    8/17/2021$55.00 → $53.00Buy
    HC Wainwright & Co.
    8/2/2021$58.00Buy
    Craig Hallum
    More analyst ratings

    $FMTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Sickle Cell Disease Association of America & Partners Launch New PSA to Boost Awareness and Understanding of the Disease

      The "Believe it!" Campaign Will be Featured on TV Networks and Radio Stations Across the U.S., Driving Viewers to SCDBelieveIT.org The Sickle Cell Disease Association of America, Inc. (SCDAA), in partnership with Forma Therapeutics, Inc. (NASDAQ:FMTX) today announced that they have joined forces to create a public service announcement (PSA) to drive awareness and advance meaningful understanding of sickle cell disease (SCD). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220930005106/en/ SCD occurs in one in every 365 Black Americans and affects an estimated 100,000 individuals in the U.S. 1 alone, according to the Centers for D

      9/30/22 9:00:00 AM ET
      $FMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Novo Nordisk to acquire Forma Therapeutics and expand presence in sickle cell disease and rare blood disorders

      Novo Nordisk and Forma Therapeutics, Holdings Inc. (NASDAQ:FMTX) today announced that they have entered into a definitive agreement under which Novo Nordisk will acquire Forma Therapeutics for $20 per share in cash, which represents a total equity value of $1.1 billion. Forma Therapeutics is a clinical-stage biopharmaceutical company focused on transforming the lives of patients with sickle cell disease (SCD) and rare blood disorders. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220901005393/en/ The acquisition of Forma Therapeutics, including its lead development candidate, etavopivat, is aligned with Novo Nordisk's strategy t

      9/1/22 8:00:00 AM ET
      $FMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Forma Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

      Announced analyses from Phase I study of etavopivat in sickle cell disease indicated reduction of reported pain-related adverse events, supporting potential to reduce vaso-occlusive crises Recently entered into an exclusive license agreement with Rigel Pharmaceuticals, Inc. for olutasidenib, a mutant IDH1 inhibitor for the potential treatment of relapsed or refractory acute myeloid leukemia Highlighted progress across portfolio at inaugural Research and Development (R&D) Day Appointed new members of Executive Team to prepare for growth in late-stage clinical development and commercialization Cash balance of $395.9 million positions company with runway through the third quarter of 2024

      8/5/22 7:00:00 AM ET
      $FMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FMTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald resumed coverage on Forma Therapeutics with a new price target

      Cantor Fitzgerald resumed coverage of Forma Therapeutics with a rating of Overweight and set a new price target of $21.00 from $46.00 previously

      6/13/22 7:18:38 AM ET
      $FMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Leerink reiterated coverage on Forma Therapeutics Hldgs with a new price target

      SVB Leerink reiterated coverage of Forma Therapeutics Hldgs with a rating of Outperform and set a new price target of $40.00 from $54.00 previously

      11/12/21 1:07:48 PM ET
      $FMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Forma Therapeutics Hldgs with a new price target

      HC Wainwright & Co. reiterated coverage of Forma Therapeutics Hldgs with a rating of Buy and set a new price target of $53.00 from $55.00 previously

      8/17/21 6:25:41 AM ET
      $FMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FMTX
    SEC Filings

    See more
    • SEC Form 15-12G filed by Forma Therapeutics Holdings Inc.

      15-12G - Forma Therapeutics Holdings, Inc. (0001538927) (Filer)

      10/24/22 11:22:28 AM ET
      $FMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Forma Therapeutics Holdings Inc.

      EFFECT - Forma Therapeutics Holdings, Inc. (0001538927) (Filer)

      10/18/22 12:15:07 AM ET
      $FMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Forma Therapeutics Holdings Inc.

      S-8 POS - Forma Therapeutics Holdings, Inc. (0001538927) (Filer)

      10/14/22 9:27:29 AM ET
      $FMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FMTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Lesser Brian Andrew closing all direct ownership in the company

      4 - Forma Therapeutics Holdings, Inc. (0001538927) (Issuer)

      10/14/22 4:07:40 PM ET
      $FMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Potts Jeannette closing all direct ownership in the company

      4 - Forma Therapeutics Holdings, Inc. (0001538927) (Issuer)

      10/14/22 4:07:33 PM ET
      $FMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Frederick Wayne A.I. closing all direct ownership in the company

      4 - Forma Therapeutics Holdings, Inc. (0001538927) (Issuer)

      10/14/22 4:07:15 PM ET
      $FMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FMTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Forma Therapeutics Holdings Inc. (Amendment)

      SC 13G/A - Forma Therapeutics Holdings, Inc. (0001538927) (Subject)

      2/14/23 8:34:06 AM ET
      $FMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Forma Therapeutics Holdings Inc. (Amendment)

      SC 13D/A - Forma Therapeutics Holdings, Inc. (0001538927) (Subject)

      10/14/22 4:03:32 PM ET
      $FMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Forma Therapeutics Holdings Inc. (Amendment)

      SC 13D/A - Forma Therapeutics Holdings, Inc. (0001538927) (Subject)

      9/2/22 4:30:10 PM ET
      $FMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FMTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Forma Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

      Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX), a clinical-stage biopharmaceutical company focused on sickle cell disease, prostate cancer and other rare hematologic diseases and cancers, today announced that its Board of Directors granted to Agustín Melián, M.D. and Linea Aspesi non-qualified stock options of 118,000 and 59,000 shares, respectively, of its common stock pursuant to Inducement Non-Qualified Stock Option Agreements (the "Stock Options") and 79,000 and 39,000 restricted stock units, respectively, pursuant to Inducement Restricted Stock Unit Agreements (the "RSUs," and together with the Stock Options, the "Inducement Grants"). On June 30, 2022, Forma announced the appointment

      7/12/22 7:05:00 AM ET
      $FMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Forma Therapeutics Announces Appointment of Acclaimed Global Sickle Cell Disease Leader Ifeyinwa Osunkwo, MD, MPH, as Senior Vice President, Chief Patient Officer

      Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced the appointment of Ifeyinwa (Ify) Osunkwo, MD, MPH, to the executive leadership team as the company's inaugural chief patient officer and senior vice president. In this role, Dr. Osunkwo will be responsible for realizing Forma's vision to transform the lives of patients by improving access and care through partnerships with global patient and community stakeholders. She will join Forma in the first quarter of 2022. "This appointment of a chief patient officer boldly represents our commitment to advancing both patient access and care a

      11/30/21 7:05:00 AM ET
      $FMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Forma Therapeutics Announces Appointment of Industry Veteran John E. Bishop, Ph.D., as Chief Technology Officer

      Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced the appointment of John E. Bishop, Ph.D., to the leadership team as senior vice president and chief technology officer. In this role, Dr. Bishop will lead chemistry, manufacturing and control (CMC)-related functions and quality, encompassing Forma's early pipeline through commercial product. "We are fortunate to welcome John to Forma at this pivotal time in Forma's history," said Frank Lee, chief executive officer of Forma. "John's extensive expertise in small-molecule pharmaceuticals and proven track record as a leader will help to e

      6/14/21 7:05:00 AM ET
      $FMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FMTX
    Financials

    Live finance-specific insights

    See more
    • Novo Nordisk to acquire Forma Therapeutics and expand presence in sickle cell disease and rare blood disorders

      Novo Nordisk and Forma Therapeutics, Holdings Inc. (NASDAQ:FMTX) today announced that they have entered into a definitive agreement under which Novo Nordisk will acquire Forma Therapeutics for $20 per share in cash, which represents a total equity value of $1.1 billion. Forma Therapeutics is a clinical-stage biopharmaceutical company focused on transforming the lives of patients with sickle cell disease (SCD) and rare blood disorders. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220901005393/en/ The acquisition of Forma Therapeutics, including its lead development candidate, etavopivat, is aligned with Novo Nordisk's strategy t

      9/1/22 8:00:00 AM ET
      $FMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Forma Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

      Announced analyses from Phase I study of etavopivat in sickle cell disease indicated reduction of reported pain-related adverse events, supporting potential to reduce vaso-occlusive crises Recently entered into an exclusive license agreement with Rigel Pharmaceuticals, Inc. for olutasidenib, a mutant IDH1 inhibitor for the potential treatment of relapsed or refractory acute myeloid leukemia Highlighted progress across portfolio at inaugural Research and Development (R&D) Day Appointed new members of Executive Team to prepare for growth in late-stage clinical development and commercialization Cash balance of $395.9 million positions company with runway through the third quarter of 2024

      8/5/22 7:00:00 AM ET
      $FMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rigel Pharmaceuticals and Forma Therapeutics Announce Licensing Agreement for Olutasidenib, a Novel Mutant IDH1 Inhibitor for the Potential Treatment of Relapsed or Refractory Acute Myeloid Leukemia

      Registrational Phase 2 data demonstrate olutasidenib's potential as a market-leading, oral, mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor for the treatment of relapsed or refractory acute myeloid leukemiaFDA has accepted Forma's NDA for olutasidenib, with a PDUFA target action date of February 15, 2023Forma to receive an upfront payment of $2.0 million and is eligible to receive an additional $17.5 million upon the achievement of certain near-term regulatory, approval, and first commercial sale milestones, as well as potential future development and commercial milestone payments of $215.5 million and tiered royalties in the low-teens to mid-thirtiesIf approved, olutasidenib would be Ri

      8/2/22 4:01:00 PM ET
      $FMTX
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care